AUTHORS
Sami Sebastian Khaznadar, MD, MSc, Chiara Adina Hummel, MD2, Zachary Hunzeker, MD3, James Hill, MD4, Ruitao Lin, PhD5, Karmila Murphy, NP-C6, Amy A. Ayers7, Jared Henderson, PhD8, Tania Patricia Sainz, BS9, Christopher R. Flowers Jr, MD, MS10, Mark P Hamilton, MD11, Michael Green, PhD12, Francisco Vega Sr, MD PHD13, Anath Christopher Lionel, MD, PhD14, Dai Chihara, MD, PhD15
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Prior epidemiological data demonstrated a nearly fivefold increased bidirectional risk between B-cell lymphomas (BCL) and T-cell lymphomas (TCL). However, sequentially occurring dual-lineage lymphomas are rare, and outcome data remain limited. We present survival data from a large single-center cohort of patients with dual B- and T-cell lymphomagenesis.
Methods: We retrospectively identified 112 patients with dual BCL and TCL diagnoses from separate biopsies at MD Anderson Cancer Center between January 2013 and May 2026. Variables analyzed included lymphoma subtypes, time to second lymphoma, overall response rate (ORR), relapse rates and survival. Progression-free survival (PFS) was calculated after first-line therapy for each lymphoma diagnosis and overall survival (OS) from the time of first lymphoma diagnosis. Cases with large B-cell lymphoma, plasmablastic lymphoma or any transformed low- to high-grade lymphoma were grouped as aggressive B-cell lymphoma (aBCL). Cases with chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma and mantle cell lymphoma were grouped as indolent BCL (iBCL). Cases with classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma were grouped as Hodgkin lymphoma (HL). Chronological sequence of lymphoma diagnosis is indicated by first/second. Listed percentages relate to the total cohort.
Results: The most common combinations of BCL and TCL were aBCL and peripheral T-cell lymphoma (PTCL) (n=35, 31.2%), iBCL and PTCL (n=25, 22.3%), iBCL and cutaneous T-cell lymphoma (CTCL) (n=17, 15.2%), aBCL and CTCL (n=8, 7.1%). Median time to second-lineage lymphoma diagnosis was 2.9 years [interquartile range, 0.9–6.7]. Survival differed substantially by subtype combination and was poorest in patients with both aBCL and PTCL with 26 total deaths (74.3%). Median OS for this group was 6.4 years [95% CI, 2.4–11.8] from first lymphoma diagnosis and 1.0 years [95% CI, 0.6–2.1] from second lymphoma diagnosis. In contrast, patients with neither PTCL nor aBCL showed a superior median OS of 13.2 years [95% CI, 8.2–18.0] from first lymphoma diagnosis and 6.2 years [95% CI, 4.0–13.2] from second diagnosis. Survival estimates varied by sequence of diagnoses with an inferior median OS for PTCL/aBCL of 3.1 years [95% CI, 0.2–not reached] and aBCL/PTCL of 6.5 years [95% CI, 2.1–12.8], whereas iBCL/CTCL formed the most favorable subgroup with a median OS of 17.1 years [95% CI, 8.2–18.0]. TCL diagnosed first was associated with a shorter median OS of 6.9 years [95% CI, 3.4–not reached], compared with a median OS of 8.3 years [95% CI, 4.4–12.8] when TCL occurred second.
ORR to first-line therapy was 93% for first lymphoma versus 62% for second lymphoma. By subtype, ORR was highest for HL with 92.8% (n=14) and lowest for PTCL with 62.5% (n=64). Relapse after first-line therapy was most frequent for CTCL with 73.3% (n=30) and least frequent for HL with 35.7% (n=14) and aBCL with 42.6% (n=47). Median PFS was shorter for the second primary lymphoma with 1.2 years [95% CI, 0.7–1.8] compared to the first with 4.3 years [95% CI, 3.4–6.4]. When the second primary lymphoma was aBCL, median PFS was 0.7 years [95% CI, 0.2–2.2], and when the second primary lymphoma was PTCL, median PFS was 0.5 years [95% CI, 0.4–1.1].
Conclusions: Survival outcomes in patients with dual lineage lymphomas are strongly influenced by lymphoma subtypes and chronological sequence of diagnoses. The poorest survival outcomes were seen in patients with both PTCL and aBCL while those with neither of these diagnoses had more favorable outcomes. Across all analyzed lymphoma subtypes, response rates and PFS were consistently more favorable when the lymphoma occurred as the first diagnosis compared with when it occurred as the second diagnosis. The worse outcomes associated with second primary lymphoma diagnoses suggest a potential impact from clonal evolution after exposure to prior treatment. Our findings support further investigation inlarger multi-center cohorts of patients with dual BCL and TCL diagnoses.
DISCLOSURES
Sami Sebastian Khaznadar, MD, MSc: No relevant conflicts of interest to declare.